Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing's syndrome. The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing's syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks. Data from the open-label phase of the study showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia as well as other key secondary and exploratory endpoints. Per the company, patients who experienced pre-specified improvements in either or both symptoms were allowed to enter the GRACE study's randomized withdrawal phase, in which half of the patients were treated with relacorilant while the other half was given placebo for a period of 12 weeks. The primary endpoint of the GRACE study is to see the maintenance of blood pressure control in the
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 5/1/24 - Beat
CORT
Analyst Actions
- 4/23/24 - HC Wainwright
CORT
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- CORT's page on the SEC website